Browse > Article
http://dx.doi.org/10.3904/kjim.2012.27.2.203

Causes and Treatment Outcomes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in 82 Adult Patients  

Kim, Hye-In (Department of Internal Medicine, Kyungpook National University School of Medicine)
Kim, Shin-Woo (Department of Internal Medicine, Kyungpook National University School of Medicine)
Park, Ga-Young (Department of Internal Medicine, Kyungpook National University School of Medicine)
Kwon, Eu-Gene (Department of Internal Medicine, Kyungpook National University School of Medicine)
Kim, Hyo-Hoon (Department of Internal Medicine, Kyungpook National University School of Medicine)
Jeong, Ju-Young (Department of Internal Medicine, Kyungpook National University School of Medicine)
Chang, Hyun-Ha (Department of Internal Medicine, Kyungpook National University School of Medicine)
Lee, Jong-Myung (Department of Internal Medicine, Kyungpook National University School of Medicine)
Kim, Neung-Su (Department of Internal Medicine, Kyungpook National University School of Medicine)
Publication Information
The Korean journal of internal medicine / v.27, no.2, 2012 , pp. 203-210 More about this Journal
Abstract
Background/Aims: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are predominantly known as medication-induced diseases. However, at our institution, we have experienced more cases of non-drug-related SJS and TEN than expected. Therefore, we studied the difference between non-drug-related and drug-related SJS and TEN in terms of clinical characteristics and prognoses. Methods: The etiologies, clinical characteristics, and treatment outcomes for 82 adult patients with SJS and TEN were retrospectively reviewed. Results: A total of 71 patients (86.6%) were classified as having SJS, and the other 11 patients (13.4%) were classified as having TEN. Drug-related cases were more common (43, 52.4%) than non-drug-related cases (39, 47.6%). Anticonvulsants (12/82, 14.6%) and antibiotics (9/82, 11%) were the most common causative medications. Anemia (p = 0.017) and C-reactive protein of ${\geq}$ 5 mg/dL (p = 0.026) were more common in the drug-related cases than in the nondrug- related cases. Intravenous steroid therapy was used as the main treatment regimen (70/82, 85.4%). Of the 82 patients, 8 (9.8%) died during the clinical course. A univariate analysis for mortality showed statistical significance for the following: kidney function abnormality, pneumonia, hemoglobin of < 10 g/dL, and combined underlying diseases. In a multivariate analysis, only pneumonia was statistically significant (odds ratio, 25.79; p = 0.009). Conclusions: Drugs were the most frequent cause of these diseases. However, non-drug-related causes also contributed to a significant proportion of cases. Physicians should keep this in mind when documenting patient history. In addition, early recognition and treatment may be important for better outcomes.
Keywords
Stevens-Johnson syndrome; Epidermal necrolysis, toxic; Etiology; Prognosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 2008;7:598-605.   DOI   ScienceOn
2 Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 2011;7:803-813.   DOI   ScienceOn
3 Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2003;4:561-572.   DOI   ScienceOn
4 Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002;138:1019-1024.   DOI   ScienceOn
5 Tay YK, Huff JC, Weston WL. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). J Am Acad Dermatol 1996;35(5 Pt 1):757-760.   DOI
6 Mulvey JM, Padowitz A, Lindley-Jones M, Nickels R. Mycoplasma pneumonia associated with Stevens Johnson syndrome. Anaesth Intensive Care 2007;35:414-417.
7 Leigh IM, Mowbray JF, Levene GM, Sutherland S. Recurrent and continuous erythema multiforme: a clinical and immunological study. Clin Exp Dermatol 1985;10:58-67.   DOI
8 Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-153.   DOI   ScienceOn
9 Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 2008;58:33-40.   DOI   ScienceOn
10 Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 1995;102:1669-1676.   DOI
11 Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-96.   DOI   ScienceOn
12 Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990- 1992): structure and results of a population-based registry. J Clin Epidemiol 1996;49:769-773.   DOI   ScienceOn
13 Chang YS, Huang FC, Tseng SH, Hsu CK, Ho CL, Sheu HM. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea 2007;26:123-129.   DOI   ScienceOn
14 Kim EJ, Lee JB, Kwon YH, et al. A clinical study of Stevens- Johnson syndrome and toxic epidermal necrolysis over the last five-year period in the Gwangju-Chonnam area. Korean J Dermatol 2006;44:574-578.
15 Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128:35-44.   DOI   ScienceOn
16 Jeung YJ, Lee JY, Oh MJ, Choi DC, Lee BJ. Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and stevens-johnson syndrome. Allergy Asthma Immunol Res 2010;2:123-126.   DOI   ScienceOn
17 Wetter DA, Camilleri MJ. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo Clin Proc 2010;85:131-138.   DOI   ScienceOn
18 Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987;123:1160-1165.   DOI   ScienceOn
19 Correia O, Chosidow O, Saiag P, Bastuji-Garin S, Revuz J, Roujeau JC. Evolving pattern of drug-induced toxic epidermal necrolysis. Dermatology 1993;186:32-37.   DOI   ScienceOn
20 Stewart MG, Duncan NO 3rd, Franklin DJ, Friedman EM, Sulek M. Head and neck manifestations of erythema multiforme in children. Otolaryngol Head Neck Surg 1994;111(3 Pt 1):236-242.
21 Khoo AK, Foo CL. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns 1996;22:275-278.   DOI   ScienceOn
22 Pushker N, Tandon R, Vajpayee RB. Stevens-Johnson syndrome in India-risk factors, ocular manifestations and management. Ophthalmologica 2000;214:285-288.   DOI   ScienceOn
23 French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006;55:9-16.   DOI   ScienceOn
24 Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007;56:181-200.   DOI   ScienceOn
25 Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 2007;87:144-148.   DOI   ScienceOn
26 Araki Y, Sotozono C, Inatomi T, et al. Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset. Am J Ophthalmol 2009;147:1004-1011.   DOI   ScienceOn
27 Faye O, Roujeau JC. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs 2005;65:2085-2090.   DOI   ScienceOn
28 Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004;25:81-88.   DOI   ScienceOn
29 Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004;25:246-255.   DOI   ScienceOn